Depression risk is exacerbated by genetic factors and stress exposure; however, the biological mechanisms through which these factors interact to confer depression risk are poorly understood. One putative biological mechanism implicates variability in the ability of cortisol, released in response to stress, to trigger a cascade of adaptive genomic and non-genomic processes through glucocorticoid receptor (GR) activation. Here, we demonstrate that common genetic variants in long-range enhancer elements modulate the immediate transcriptional response to GR activation in human blood cells. These functional genetic variants increase risk for depression and co-heritable psychiatric disorders. Moreover, these risk variants are associated with inappropriate amygdala reactivity, a transdiagnostic psychiatric endophenotype and an important stress hormone response trigger. Network modeling and animal experiments suggest that these genetic differences in GR-induced transcriptional activation may mediate the risk for depression and other psychiatric disorders by altering a network of functionally related stress-sensitive genes in blood and brain.
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In Brief
Using a stimulated eQTL approach, Arloth et al. show that common genetic variants that alter the initial transcriptome response to stress hormone receptor activation also cumulatively increase the risk for stress-related psychiatric disorders and predict a threat response from the amygdala.
INTRODUCTION
Major depressive disorder (MDD) has a lifetime prevalence of up to 17% (Kessler et al., 2005) , resulting in one of the highest global burden of disease ratings by the World Health Organization (Ustü n et al., 2004) . Despite its prevalence and impact, the etiological and pathophysiological mechanisms underlying MDD are poorly understood, resulting in sub-optimal treatments with high rates of recurrence and treatment resistance (Warden et al., 2007) . Family, twin, and population studies point to both genetic as well as environmental risk factors for depression. Genetic factors contribute up to 40% of the risk and are complemented largely by individual-specific environmental exposure to adverse life events (Kendler et al., 2006) . Both sensitivity and resilience to the long-term effects of exposure to adverse life events may be modulated by genetic variation (Kendler, 2013) .
Stress results in activation of the stress hormone system, which culminates in the activation of glucocorticoid receptors (GRs) by cortisol. The GR is a nuclear hormone receptor, and upon activation it translocates from the cytoplasm to the nucleus, where it binds to glucocorticoid response elements (GREs) and regulates gene expression (McKay and Cidlowski, 1999; Phuc Le et al., 2005) . Activation of this receptor not only initiates adaptive physiological changes in the body to confront an imminent threat, but also facilitates the termination of these changes once the threat has been overcome. Thus, genetically driven variability in GR regulation of the stress hormone response may functionally interact with environmental risk factors, thereby producing individual differences in risk for MDD. Consistent with this model, dysfunction of GR-mediated negative feedback has been reported in MDD (de Kloet et al., 2005) as well as in individuals exposed to early adversity (Heim and Binder, 2012; Wilkinson and Goodyer, 2011) , one of the strongest risk factors for the development of MDD. Moreover, genetic variation in pathways regulating GR signaling has been linked with MDD risk (van Rossum et al., 2006) . Here, we show that SNP  rs58712964  rs6741290  rs6439 rs6439982 982  rs1150598  rs17239727  rs10261398  rs1178 rs11788797 8797  rs12417156  6006  rs600638 38  rs1105 rs11055463 5463  rs4129 rs41291211 1211  rs1571385  rs3607 rs36074193 4193  2302  rs2302585 585  rs6049 rs6049 rs60492890 2890 2890   SNP Position  111833649  10182160  142422 142422118 118  13305420  43810846  65387599  129981 129981562 562  74107635  117462 117462960 960  777092 7770921 1  113793 113793054 054  60706864  463380 46338098 98  199427 1994271 1  122636 122636 1226368 8 8   Probe ID  ILMN_1733259  ILMN_1775011  ILMN 1  _ 706598  ILMN_1736982  ILMN_2081335  ILMN 1  ILMN_1651950 651950  ILMN_2413064  ILMN 1  ILMN_1652753 652753  ILMN 1  ILMN_1746516 746516  ILMN 1  ILMN 1  ILMN_1665457 665457 665457  ILMN_1782292  ILMN_2410516  ILMN 1  ILMN_1672004 672004  ILMN 1  ILMN_1721344 721344  ILMN_1674926   Probe Gene  ADORA3  NOL10  ACPL2  PHACTR1  C7orf44  TPST1 TPST1  ST6GALNAC4  P PAAF1 AAF1  P P P  RPS25 RPS25  CLEC4C CLEC4C CLEC4C  LAMP1  PPM1A  T TOB1 OB1  MOB3A MOB3A C19orf35
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of Experiments and Analyses Applied in This Study
The main hypothesis tested in this study is that common genetic variants that alter the short-term transcriptional response to GR activation also alter the risk for stress-related psychiatric disorders and related neural endophenotypes.
experiments suggest that these genetic differences in the transcriptional response to GR activation may mediate risk for depression and other psychiatric disorders by altering a network of co-expressed genes that are responsive to stress and glucocorticoids in the brain. In addition, these genetic variants shape the response of the amygdala, which is itself an important trigger of the stress hormone response and a functional neural phenotype implicated in the etiology and pathophysiology of depression and other forms of psychopathology (Jankord and Herman, 2008; Phillips et al., 2003) . The main hypotheses and the experimental approach are summarized in Figure 1 .
RESULTS

Genetic Regulation of GRStimulated Gene Expression
We first identified genetic variants that alter GR-stimulated gene expression changes by adopting a stimulated expression quantitative trait locus (eQTL) approach ( Figure 2A ). Gene expression profiles in peripheral blood cells from 160 male individuals of the Max-Planck Institute of Psychiatry (MPIP) cohort (91 cases and 69 controls, see Experimental Procedures) were obtained at baseline and 3 hr after stimulation with the selective GR agonist dexamethasone (Figure S1A) and combined with genomewide SNP data. All individuals showed a strong endocrine response to dexamethasone (Cortisol: F 1,159 = 43.93, p = 5.02 3 10 À10 and ACTH: F 1,158 = 37.96, p = 5.76 3 10 À9 ; Figures S1B and S1C).
After quality control, 4,447 gene expression probes that exhibited strong regulation following dexamethasone administration (absolute fold change in gene expression from baseline to 3 hr postdexamethasone R 1.3 in at least 20% of all samples) were combined with genotype data of $2 million imputed SNPs (see Experimental Procedures). Using the log fold change in gene expression standardized to baseline values as the outcome and restricting the analysis to a ± 1 Mb cis-region around each probe, we found that 3,820 GR-response-modulating cis-eQTLs (GRresponse eQTLs) remained significant after accounting for disease status, age, and BMI and correction for multiple testing (see Experimental Procedures). These comprised 297 unique array probes and 3,662 unique SNPs. The 3,662 unique GRresponse cis-expression SNPs (eSNPs) can be summarized in terms of independent tag SNPs into 296 uncorrelated GRresponse cis-eSNP bins, i.e., sets of SNPs in linkage (B) Circularized Manhattan plot displaying cis-associations for GR-response eQTL bins (n = 320) and their respective significance (Àlog 10 Q values). Displayed from the outer to the inner circle are the number of chromosomes, the ideograms for the human karyotype (hg18), genes nearby eSNPs, and Manhattan plots for the eQTL bins that survived correction for multiple testing. (C and D) Boxplots of human gene expression values for ADORA3, which is an example of a significant GR-response eQTL. Expression levels are stratified based on the eSNP genotypes for ADORA3. Baseline (6 p.m.) measures are displayed in blue and GR-stimulated measures (9 p.m.) in red. Microarrays data are displayed in (C) and their qPCR validation in (D). Q value in (C) is derived from GR-response cis-eQTL analysis and the p value in (D) from the qPCR linear regression model. disequilibrium (LD; see Experimental Procedures). We defined the tag eSNP as the eSNP showing the highest association per bin (lowest Q value). These 296 GR-response cis-eSNP bins correspond to 320 GR-response cis-eQTL bins, i.e., cis-eSNP bin-probe combinations, as one cis-eSNP bin can be associated with the regulation of more than one transcript and vice versa. These GR-response cis-eQTL bins are listed in Table S1 and illustrated in Figures 2B-2D . Including dexamethasone serum levels or the blood cell count as covariate did not change the results, excluding any confounding effects of individual differences in dexamethasone concentration and cellular composition (see Supplemental Information).
To assess the robustness of these GR-response eQTLs, we validated them in an independent sample of n = 58 (see Experimental Procedures) by performing a sample size-weighted Z score meta-analysis across both samples. In this analysis, 72% of the GR-response eQTLs could be validated, i.e., showed a meta-analysis p value equal to or more significant than in the discovery sample alone (see Experimental Procedures). This method accounts for the small size of the validation sample and suggests the robustness of most of the GR-response eQTLs.
Characterization of GR-Response eSNPs
To better understand the properties of these GR-response eQTLs, we first mapped the GR-eSNPs (n = 3,662 SNPs) to GR binding regions as defined by ChIP-seq peaks in lymphoblastoid cell line (LCL) GM12878 (see Experimental Procedures). We observed a significant enrichment of GR-response eSNPs in GR binding sites as compared to random SNPs (fold enrichment = 2.4, permutation-based FDR % 0.001).
Next, we mapped the distance of the 320 GR-response eQTL bins to the genomic location of the probe sequence of the respective regulated transcript (utilizing the closest SNP within a bin) and compared this to the probe distance for baseline cis-eQTL bins, i.e., the eSNP-probe combinations that showed a significant association of the genotype with transcription levels at baseline (see Supplemental Information). The GR-response eSNP bin-toprobe distance (mean = 406 kb, standard deviation [SD] = 303 kb, n = 320 bins) was significantly longer (Wilcoxon p value = 1.03 3 10
À50
) than baseline eSNP bin-to-probe distance (mean = 149 kb, SD = 232 kb, n = 1,148 bins; Supplemental Information). This suggests that GR stimulation is associated with significantly more long-range transcriptional regulation than baseline gene expression and that distinct regulatory elements may be involved in baseline versus GR-stimulated gene transcription.
To determine the regulatory potential of GR-response eSNPs, we investigated whether they are enriched within enhancer regions as defined by the Roadmap Epigenome Project ) (see Experimental Procedures). GR-response tag eSNPs were significantly enriched within enhancers in 62 different tissues, including blood cells, but also non-hematopoietic tissue such as brain (see Figure S2 ). When testing baseline tag eSNPs, we only observed an enrichment in enhancers in 54% of these 62 tissues. Whether combined enrichment of both GR-response tag eSNPs and baseline tag eSNPs was observed seemed to be tissue specific (see Figure S2 ). In fact, GR-response eSNPs were more enriched in brain enhancers than baseline eSNPs, i.e., only one of the eight brain enhancers significantly enriched with GR-response eSNPs also displayed a significant enrichment for baseline eSNPs (see Figure 3) . In contrast, we observed equal enrichment for GR-response as well as baseline eSNPs in primary hematopoietic tissues (see Figure S2 ). These results further support the viewpoint that GR-response eSNPs affect different transcriptional regulators than baseline eSNPs and suggest possible cross-tissue effects of these SNPs.
To evaluate whether the long-range regulation of GRresponse eQTLs may be associated with long-range physical chromatin interaction, we compared our data with that from a chromatin interaction analysis with paired-end tag sequencing (ChIA-PET) generated by ENCODE (ENCODE Project Consortium, 2011) in the leukemia cell line K562. For this, we examined whether regions containing the GR-response eSNP bin and the corresponding probe gene overlap with physically interacting ChIA-PET tags (see Experimental Procedures). Twenty-five percent of the GR-response eSNP bin-probe gene combinations overlapped with chromatin interaction signals. This was significantly greater than 1,000 equally sized sets of randomly distributed GR-response eSNP bin, especially when restricting the analysis to more long-range eSNP bin-probe gene pairs with distances > 100 kb (fold enrichment >100kb = 1.57, permutationbased FDR >100kb = 0.007; see Experimental Procedures). To 
GR-Response eSNPs Are Enriched in Enhancer Regions in Multiple Tissues
Bar graph illustrating the enrichment of GRresponse eSNPs for enhancers in multiple tissues from the Roadmap Epigenome Project, including brain tissue. The x axis shows the fold enrichment and the y axis all brain enhancers all well as the mean fold enrichment among all hematopoietic cells (see Figure S2 ) and brain enhancers. The fold enrichment for GR-response eSNPs is illustrated in red and for the permuted baseline eSNPs in blue. Only the GR-response eSNP enrichment, which passes a Bonferroni corrected significance threshold (corrected for the number of all tested tissues or cells, n = 62) is illustrated. * p % 0.05, obtained by binomial enrichment test and Bonferroni correction, error bars ± SD.
validate these long-range chromatin interactions, we used a chromatin conformation capture (3C) assay to confirm a physical interaction between the eSNP bin regions of the GR-response eSNP tag rs1379868 in the NRTN locus and the corresponding GR-stimulated transcript LONP1 (see Figures 4A and 4B) , which is over 130 kb upstream. This eSNP bin includes a GR binding site and ChIA-PET tags (see Figure 4C ), which interact with the transcription start site of the LONP1 gene. The 3C assay confirmed an increased chromatin interaction (p = 3.35 3 10 À23 , c 2 = 115.15 at baseline) of the eSNP bin with the TSS of the LONP1 gene (P4 in Figures 4C and 4D ) in five LCLs. The average interaction frequency of these two sites was higher following stimulation with the GR-agonist dexamethasone (4.83 versus 5.65). These results suggest that long-range regulation of GR-response eQTLs could be mediated by direct chromatin interaction of enhancer regions with the respective transcription start sites.
GR-Response eSNPs Are Enriched in Loci Nominally
Associated with MDD and Other Psychiatric Disorders as well as in Genome-wide Significant Schizophrenia Loci Besides their functional characterization, an important question was to assess whether the genetic variants that alter the immediate transcriptional response to GR activation (GR-response eSNPs) would also be associated with risk for stress-related psychiatric disorder. To assess this, we first tested whether our GRresponse eSNPs were overrepresented among SNPs associated with MDD in the genome-wide association study (GWAS) results of the Psychiatric Genomics Consortium (PGC), which includes approximately 9,000 cases and the same number of controls . Among nominally associated loci with MDD (at meta-analysis p value % 0.05), 282 SNPs also represent a GR-response eSNP. Permutation analysis (see Experimental Procedures) predicted an expected mean overlap of 210 SNPs from 1,000 randomly selected SNP sets (fold enrichment = 1.34, permutation-based FDR < 0.001; Figure 5A ). We next investigated whether GR-response eSNPs were also enriched over baseline eSNPs, as SNPs associated with transcriptional changes have been shown to be more enriched in GWASs in general (Roussos et al., 2014) . Again the mean overlap for 1,000 permuted baseline cis-eSNP sets (218 SNPs) was significantly lower than the actual overlap of GR-response eSNPs (fold enrichment = 1.29, permutation-based FDR < 0.001; Figure 5A ). These enrichments remain significant when using only the tag eSNPs (n = 285) to control for possible confounding due to linkage disequilibrium (LD) structure (fold enrichment = 1.31, permutation-based FDR = 0.082).
The 282 GR-response eSNPs that overlap with MDD-associated SNPs correspond to 23 unique eSNP bins (reflecting 26 eQTL bins) that regulate 25 unique transcripts (Table S2) . We call these 23 eSNP bins ''MDD-related GR eSNP bins'' in the remainder of the manuscript to refer to GR-response eSNPs that also show a nominal association with MDD.
Validation of Enrichment and Extension to Other Psychiatric Disorders
We next examined whether these MDD-related GR eSNPs would also be associated with MDD in an independent sample. For this we constructed a genetic risk profile score (GRPS) using the tagging SNPs of the 23 MDD-related GR eSNP bins for each individual in an independent validation sample of 1,005 MDD cases and 478 controls (Table S3 ; see also Experimental Procedures). We found these GRPSs to be significantly associated with MDD and that individuals with higher GRPSs were overrepresented in the case group (Z = 3.76, p = 0.00017; Figure 5B ). This GRPS explains about 2.6% of the total variance for MDD in this sample, and the association of these MDD-related GR eSNP GRPSs was more significant than GRPSs constructed from 1,000 randomly generated SNP profiles (permutationbased FDR = 0.008; see Experimental Procedures).
As exposure to stressful life events is a strong risk factor not only for MDD but also for other psychiatric disorders, including bipolar disorder (BPD) and schizophrenia (SCZ) (Dohrenwend and Egri, 1981; Kendler and Karkowski-Shuman, 1997) , we tested whether the GR-response eSNPs were also overrepresented among SNPs associated with other psychiatric disorders utilizing meta-analysis data from the PGC. Using this approach, we tested for for significant GR-response eSNP enrichment compared to 1,000 randomly generated baseline eSNP sets in the PGC for four additional psychiatric disorders and the cross-disorders analysis including also MDD (see Table 1 ). In the latest multi-stage SCZ GWAS, which includes up to 36,989 cases and 113,075 controls (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), we detected a significant enrichment of GR-response eSNPs compared to baseline eSNPs with SNPs associated with SCZ at p % 0.05 (fold enrichment 1.29, permutation-based FDR % 0.001). When we limited the enrichment analysis to genome-wide significant SCZ loci, we detected 134 GR-response eSNPs that overlapped SNPs associated with SCZ at p % 5 3 10 À8 . This corresponds to a 10-fold enrichment over baseline eSNPs and is 7.75-fold higher than for nominally associated SCZ SNPs (see Table 1 ). A significant negative enrichment was identified for loci associated with attention deficit-hyperactivity disorder (permutation-based FDR % 0.012; ADHD; 840 cases and 1,947 trio cases) and autism spectrum disorder (ASD; permutation-based FDR % 0.001; 161 cases and 4,788 trio cases) but not BPD (see Table 1 ).
To test whether these enrichments of GR-response eSNPs as compared to baseline eSNPs are specific to psychiatric disorders, we mapped these variants to GWAS for rheumatoid arthritis, Crohn's disease, and height but found no enrichment more than 1.06-fold (see Table 1 ). These analyses suggest that GR-response eSNPs are unrelated to these medical disorders or general quantitative traits but specifically contribute to the risk for MDD and SCZ.
Functional Relevance of Transcripts Regulated by MDD-Related GR eSNPs Gene Network Analysis of MDD-Related GR Genes Next, we investigated whether the probe genes (n = 24), regulated by the MDD-related GR eSNPs, are part of specific pathways that may be relevant for the pathophysiology of psychiatric disorders. Using the GeneMANIA tool (Montojo et al., 2014) , we were able to generate a gene network containing 23 of the 24 MDD-related GR genes (see Figure 6A and Experimental Procedures). Within this network, the type of interactions between the MDD-related GR genes that were most enriched were: coexpression (1.21 times the number expected when using other GR-stimulated transcript sets), co-localization (genes are expressed in the same tissue or proteins are found in the same location; fold enrichment = 1.21), and shared protein domains (fold enrichment = 3.77). Several genes, e.g., FTH1, CCT7, RPS2, IMPDH2, and PELI1, presented more than ten interactions. Additional co-expression analysis identified that the MDD-related GR genes are more tightly co-regulated in blood than in 1,000 sets of randomly chosen transcripts selected from all GR-responsive transcripts (fold enrichment = 1.04, permutation-based FDR = 0.078). These data provide support that the MDD-related GR genes functionally interact to perform an orchestrated function, i.e., they are coordinated in their transcriptional response to GR activation or stress. A limited network analysis through manually curated interactions from the scientific literature (Lechner et al., 2012) revealed that these genes show associations with MDD, SCZ, BPD, neurodevelopmental disorders, posttraumatic stress disorder, and response to antidepressant treatment in independent datasets (see Figure S3 ). In addition, they seem predominantly involved in pathways associated with ubiquitination and proteasome degradation and the inflammatory response, systems that have been implicated in the pathophysiology of MDD and SCZ, as well as in stressrelated changes in synaptic plasticity (Miller et al., 2009 ; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Tai and Schuman, 2008) .
Convergent Functional Genomics: Integrating Human MDD-Related GR Genes with Relevant Mouse Models
To establish whether the transcripts regulated by acute GR activation in blood are also regulated in the brain within a similar time frame, we investigated whether the orthologs of the 24 MDDrelated GR transcripts were differentially regulated in mouse blood and brain (prefrontal cortex [PFC] , hippocampus [HC] , and amygdala [AM]) 4 hr following dexamethasone administration (10 mg/kg dexamethasone i.p.). In this experiment, 17 of the 24 genes had a mouse orthologous gene, and 16 were expressed above microarray detection threshold. One-third of the genes showed significant changes at FDR % 0.1 and 53.3% at p % 0.05 in one or more of the investigated brain regions. Over 86% of the genes were significantly regulated (FDR % 0.1) in mouse blood (see Figure 6B left panel).
In order to extend these results from pharmacologic GR agonism, we further evaluated whether acute social defeat stress, which is commonly used to induce depressive-like behavior, differentially regulates these same 24 MDD-related genes in mice. In this experiment, 17 orthologous genes were analyzed in blood, PFC, AM, and HC samples 4 hr after exposure to an aggressive resident mouse with short attack latency . Here, three (MKNK2, SLCO3A1, and OCIAD2) of the five genes that were significantly differently regulated after dexamethasone stimulation were also significantly regulated following social defeat (FDR % 0.1) in in one or more of the analyzed brain regions (see Figure 6B right panel). This suggests that a subset of MDD-related GR genes is also regulated by acute social defeat, providing an important extension to stress-related risk for depression.
Cumulative Risk Scores for the MDD-Related GR eSNPs Correlate with Dysfunctional Amygdala Reactivity To investigate the relationship between MDD-related GR eSNPs and variability in stress-related brain function in humans, we applied an imaging genetics strategy to data from 647 participants (171 individuals with current or past DSM-IV Axis I disorders and 476 controls; 306 of participants were self-reported European-Americans [EUR-AM]; Table S5 and see also Experimental Procedures) of the Duke Neurogenetics Study (DNS) (see Experimental Procedures). Our analyses focused on centromedial amygdala reactivity to canonical threat-related angry and fearful facial expressions ( Figure 7A ), because this phenotype is clearly implicated in the etiology and pathophysiology of stressrelated disorders, including depression (Phillips et al., 2003) . Moreover, amygdala reactivity can trigger rapid physiological and behavioral responses to threat, including activation of the stress hormone response via projections from the medial division of the central nucleus of the amygdala, (captured in our analysis by our centromedial amygdala region of interest) to the paraventricular nucleus of the hypothalamus (Ulrich-Lai and Herman, 2009). Lastly, amygdala function is influenced by the slow-acting, presumably genomic effects of hydrocortisone administration (Henckens et al., 2010) , further highlighting its importance as a systems-level phenotype sensitive to our observed GR-induced transcriptional responses. Higher MDD-related GR tag eSNP GRPSs (Table S4 ; see also Experimental Procedures) were associated with blunted centromedial amygdala response to angry and fearful facial expressions relative to neutral expressions in the EUR-AM subsample, even after accounting for age, sex, and the presence of an Axis I disorder (F 1,301 = 7.06, p = 0.008; Figure 7B ). This effect was also observed in the entire sample after accounting for population stratification (F 1,637 = 6.05, p = 0.014; Figure S4A ). Permutation analyses that formed random SNP profiles (n = 1,000; matched for MAF and not exceeding the maximum correlation among profile SNPs; see Experimental Procedures) indicated that the actual GRPS were more likely to be associated with these differences in amygdala reactivity than 1,000 sets of random SNP profiles (EUR-AM subsample: permutation-based FDR = 0.003; entire sample: permutation-based FDR = 0.012). Post hoc analyses revealed that this differential effect was driven by higher centromedial amygdala reactivity to neutral facial expressions relative to our control condition in participants with higher GRPS (EUR-AM subsample: F 1,301 = 6.47, p = 0.011; Figure 7D ; entire sample: F 1,637 = 8.52, p = 0.004; Figures  S4A and S4C ). There were no effects of GRPS on amygdala reactivity to angry and fearful facial expressions relative to our control condition (EUR-AM subsample: F 1,301 = 0.2, p = 0.65; Figure 7C and entire sample: F 1,637 = 0.09, p = 0.76; Figures  S4A and S4B ).
This pattern of altered amygdala reactivity in individuals with higher GRPS is suggestive of impaired threat-related cue learning with inappropriately increased reactivity to neutral expressions, which do not convey threat (Britton et al., 2011; Oliveira et al., 2013) . Thus, higher GRPS may be associated with non-specific or overgeneralized threat and stress responses, which are consistently observed in depression as well as other mood and anxiety disorders (Britton et al., 2011; Oliveira et al., 2013) .
DISCUSSION
We have shown that common variants in long-range enhancer elements alter the transcriptional responsiveness of GR target genes to the GR and that these variants cumulatively increase the risk for psychiatric disorders, including MDD and SCZ. These findings suggest that the risk of developing MDD after adverse life events may be influenced by an individual's sensitivity to the downstream, transcriptional effects of cortisol released during the stressful adverse events. In addition, the findings suggest that the changes seen in the initial transcriptional response to stress may influence how an individual processes stressful exposures. Indeed, the risk variants were also associated with overgeneralized centromedial amygdala reactivity to non-threat stimuli. This is consistent with dysfunctional behavioral and physiological hyper-responsiveness to threat in MDD and other psychiatric disorders. One of our notable genetic findings is that the distance between the GR-response eSNPs and the regulated gene expression probe was significantly longer than the distances previously reported for baseline eQTLs (149 kb baseline eQTLs versus 406 kb for GR-response eQTLs in our dataset). Our data support and extend previous observations that indicated a long-range transcriptional regulation by the GR (Hakim et al., 2011; John et al., 2011; So et al., 2007) . In fact, a combined analysis of our GRresponse eQTLs and ChIA-PET data from the ENCODE project (ENCODE Project Consortium, 2011) as well as a validation using 3C analysis suggests that there could be a physical long-range interaction between the eSNP locus and the promoter of the GR-regulated transcript for at least 25% of the GR-response eQTLs. Additional experiments are necessary in order to investigate the direct effects of the different alleles on the enhancer function and chromatin conformation in other tissues, including the brain, to further validate this.
More broadly, our results indicate that stimulated eQTL approaches using disease-risk-relevant transcriptional stimuli (in our case GR activation and stress) can identify novel risk genes for common disorders that may otherwise go undetected. Previous studies have used eQTLs or DNA methylation QTLs (mQTLs) for the annotation of GWAS results and indicated the importance of using eQTLs and mQTLs from disease-relevant tissues (Gamazon et al., 2013; . While we do not observe a significant enrichment of baseline blood eQTLs, GR-response eQTLs from this tissue were significantly enriched, even over baseline SNPs, among the variants associated with MDD and SCZ (see Table 1 ). Interestingly, GR-response eSNPs identified in whole blood were enriched in enhancers specific to brain tissue, while this was not the case for baseline eSNPs identified in blood (see Figures 3 and S2 ). This suggests that GR-response eSNPs may have more relevance for cross-tissue effects, especially in the brain. This pattern may underlie the observation that GR-response eSNPs were associated with psychiatric disorders and amygdala function, but not with other medical disorders or height. Our findings support the notion that not only the tissue but also the type of stimulation, e.g., mimicking aspects of stress in our experiments, can be relevant for using such QTL studies in annotating GWAS results. While these common genetic variants were discovered in peripheral blood cells, we provide evidence for their importance in neural circuits that are critical for generating and regulating the stress axis response to adversity. First, GR-response eSNP regions are enriched in enhancers relevant in brain tissue. Second, a number of the transcripts affected by these MDD-related GR eSNPs in their GR-regulated gene expression in human blood were also regulated by short-term GR activation or following exposure to acute social defeat stress in the mouse hippocampus, prefrontal cortex, or amygdala. Third, using imaging genetics, we demonstrate that the cumulative MDD-related GR tag eSNP genetic risk profile predicts overgeneralized reactivity of the human amygdala. It has to be noted, however, that while the GR-response eQTLs were identified using the selective GR agonist dexamethasone, the GR shares response elements with other steroid receptors, especially the mineralocorticoid receptor, so that we cannot exclude an important contribution of these other receptors.
Furthermore, the MDD-related GR genes formed a strongly interconnected gene network (over 85% of the genes are co-expressed; Figure 6A ). Within this network, inflammation was the pathway with the highest connectivity (see Figure S3 ), and a number of studies indicate the pathophysiological relevance of this system in the development of MDD and SCZ (Haroon et al., 2012; Keller et al., 2013; Miller et al., 2009) . The role of the immune system was also supported by results of the latest GWAS meta-analysis for SCZ (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). The connectivity of this system was followed in strength by the connectivity of proteasome degradation. It has been shown, for example, that activation of GRs enhances ubiquitin/proteasomemediated degradation of glutamate receptor subunits and thereby mediates cognitive impairment induced by repeated stress exposure (Yuen et al., 2012) . Genetic modulation of GR effects on the immune system in addition to ubiquitin/proteasomemediated degradation thus provide a mechanistic link between risk for psychiatric disorders and the genetic differences in GR-induced gene expression.
Most importantly, our GR-response eQTL analysis revealed an enrichment of these GR-response eSNPs among MDD-associated SNPs over baseline eSNP sets as well as random SNP sets. This suggests that SNPs altering the initial transcriptional response to stress also influence the risk for MDD. The association was verified in an independent cohort. Furthermore, the increased risk conferred by these functional variants may extend to SCZ. This is consistent with evidence from recent studies of psychiatric disorders, which suggest shared genetic risk loci, with MDD having the highest co-heritability with BPD followed by SCZ (Lee et al., 2013) . The fact that we do not detect a significant enrichment of GR-response eSNPs with BPD, despite the large SNP co-heritability of this disorder with both SCZ and MDD, may in part be due to the smaller sample size in this meta-analysis and thus insufficient power to detect true associations (n = 6,704 cases for BPD versus over 9,000 cases for MDD and SCZ1). The fact that the fold enrichment of GR-response eSNPs with SCZ increases with sample size (SCZ1: n = 9,087 cases versus SCZ2: n = 36,989 cases) and p value cut-off (p < 0.05 and p < 5 3 10 À8 ) suggests that the strategy of using stimulated eQTL approaches may help in identifying true associations for disease. Interestingly, we find that four MDD-related GR eQTL bins, which are not only associated with MDD but also with SCZ, and the cross-disorder associations from the PGC analyses (Table 1) . This GR-response eQTL drives the overlap with genome-wide SCZ2 associations, and it has been validated using qPCR (Supplemental Information). These findings suggest that GRresponse eSNPs may contribute to the shared risk between psychiatric disorders, especially MDD and SCZ, and that this approach may delineate between shared and specific risk factors for these disorders.
Results from our imaging genetics study provide one potential neural pathway by which MDD-related GR eSNPs may increase the risk for the development of stress-related psychopathology, including depression. Interestingly, MDD-related GR eSNPs predict heightened amygdala reactivity to stimuli that do not inherently signal threat (i.e., neutral facial expressions). This suggests that MDD-related GR eSNPs associated with the immediate transcriptome response to stress may impair the neural circuitry that supports the learning of threat-related cues and, possibly, thereby contribute to the overgeneralization of threat-related stress responses. Indeed, in healthy individuals, the genomic effects of hydrocortisone result in more specific reactivity to threatening stimuli (Henckens et al., 2010) . As such, MDDrelated GR eSNPs may underpin a less adaptive and overgeneralized amygdala response that leaves individuals more likely to perceive threat in the absence of unambiguous cues; this in turn may lead to the development of cognitive biases associated with depression, or perhaps even paranoia, in the context of schizophrenia.
The data presented in this study show that common genetic variants that change the GR-mediated immediate transcriptome response to stress are linked, in the long-term, to both changes in neural processing of threat and increased risk for MDD and SCZ. Our data lend further support to the notion of a possible shared genetic liability of some psychiatric disorders and specifically point to stress-responsive genes as common risk factors. Studies dissecting how these genetic variants alter the molecular, cellular, and neural response to glucocorticoids in the short and long term could inform the development of novel strategies for the prevention and treatment of stress-related psychiatric disorders.
EXPERIMENTAL PROCEDURES Samples and Study Designs
MPIP Cohort
The subject pool for the eQTL analysis consisted of 164 male Caucasian individuals: 93 healthy probands and 71 in-patients with depressive disorders treated at the Max Planck Institute of Psychiatry's hospital in Munich, Germany (MPIP cohort; see Supplemental Experimental Procedures; for details). Baseline whole-blood samples (for plasma and RNA) were obtained at 6 p.m. after 2 hr of fasting and abstention from coffee and physical activity. Immediately afterward the participants were given 1.5 mg dexamethasone orally. A second blood draw was performed 3 hr later at 9 p.m. (see Figure 2A ). Cortisol and ACTH serum levels were determined using previously described radioimmunoassays . Plasma dexamethasone concentrations were assessed in serum samples drawn at 9 p.m. using liquid chromatography-tandem mass spectrometry on API4000 (AB Sciex). 
MARS Cohort
DNS Cohort
The imaging genetics analysis was conducted on data from (1) a EuropeanAmerican subsample of 306 participants (63 with DSM-IV Axis I disorder) and (2) a full sample of 647 participants (117 with DSM-IV Axis I disorder) of the ongoing Duke Neurogenetics Study (see Supplemental Experimental Procedures). All participants completed a widely utilized functional magnetic resonance imaging (fMRI) paradigm assessing threat-related amygdala reactivity (see Supplemental Experimental Procedures). Mouse Models Twenty-two male C57BL/6N mice were used for the dexamethasone-stimulation test (DEX-mouse). The experiment was performed twice with two separate batches of mice (n = 22 per batch). Animals were injected i.p. with either vehicle (VEH, n = 11) or 10 mg/kg dexamethasone (DEX, n = 11) between 9 a.m. and 11 a.m. Animals were sacrificed 4 hr post-injection.
The acute social defeat sample included 17 male C57BL/6N mice (n = 8 control and n = 9 acute stress mice) taken from a larger study that were used for this experiment. Mice underwent the acute social defeat stress once exactly 4 hr preceding sacrifice and tissue collection. The acute social defeat paradigm was performed as described previously on a single day between 9 a.m. and 12 p.m. (see Supplemental Experimental Procedures).
From both animal models described above, blood was collected and the brain was carefully extracted and dissected (see Supplemental Experimental Procedures). The following brain regions were collected: hippocampus (HC), prefrontal cortex (PFC), and the amygdala (AM).
All human studies have been approved by the respective local ethics committees and all individuals gave written informed consent. Details about the individual studies are listed below or in the Supplemental Experimental Procedures. The mouse model protocols were approved by the Committee for the Care and Use of Laboratory Animals of the Government of Upper Bavaria, Germany.
Gene Expression Data
The human whole-blood RNA of the MPIP cohort samples was hybridized to Illumina HumanHT-12 v3.0 array. All array probes have been subjected to an extensive quality control (QC; see Supplemental Experimental Procedures). For the GR-response eQTL analysis, only transcripts that showed a difference in gene expression between the samplings at 6 p.m. and 9 p.m. with an absolute fold change R 1.3 in at least 20% of all samples were categorized as robustly effected by dexamethasone stimulation (n = 4,630 transcripts) and further used in the analysis. The position of the array probes and possible SNPs within these sequences were annotated using ReMOAT version August 2009 (Barbosa-Morais et al., 2010), leaving 4,447 autosomal array probes for the GR-response eQTL analysis (see Supplemental Experimental Procedures).
DEX-mouse RNA samples were hybridized on Illumina MouseRef-8 v2.0 chips, and the mouse RNA from the acute social defeat mouse model was hybridized on Illumina MouseWG-8 v2.0 chips. QC was applied separately for each tissue and experiment as described in Supplemental Experimental Procedures.
Genotype Data
Human DNA from MPIP and MARS cohort subjects was extracted from EDTA blood samples and genotyped on Illumina Human610-Quad/Human660W-Quad arrays (MPIP cohort) and Illumina Sentix Human-1/HumanHap300/ Human610-Quad/HumanOmniExpress arrays (MARS cohort). From the SNP data surviving QC, imputation of additional variants was performed using IMPUTE v2 ; see Supplemental Experimental Procedures for more detail on genotyping QC and imputation).
The MARS GRPSs included alleles from 20 of the 23 tag eSNPs (three SNPs diverged from HWE in the MARS sample, see Table S3 ). See also Supplemental Experimental Procedures.
Human DNA from participants of the DNS cohort was isolated from saliva and genotyped on the Illumina HumanOmniExpress array as well as a custom array containing an additional $300,000 SNPs. The DNS GRPSs included alleles from 19 of the 23 tag eSNPs (four SNPs not present on genotyping array; see Table S4 and Supplemental Experimental Procedures).
Statistical Analysis
The eQTL analysis (MPIP cohort) was restricted to those SNP-probe pairs that map within a region of 1 Mb upstream or downstream of the gene expression probe, in order to detect cis-eQTLs. To measure the transcriptional response, we used the log fold change in gene expression changes between 6 p.m. (baseline) and 9 p.m. (GR-stimulation) standardized to baseline. PLINK v1.07 (Purcell et al., 2007) was used to test for cis-association between all imputed SNPs and transcriptional response. As eQTL data were composed of two kinds of data, genotyping and expression data, we used two stages of multiple testing correction: (1) SNP level correction: for each cis-region (array probe), we performed a permutation test. The sample identifiers in the gene expression data were shuffled in order to preserve the structure in the genotype data (LD). A total of 500,000 permutations were carried out per probe, and the empirical p values were adjusted using the Westfall-Young correction for the number of SNPs per probe, i.e., maxT procedure of WestfallYoung (Westfall and Young, 1993). (2) Probe level correction: cis-regions with an extensive LD structure will increase the number of false positive eQTLs (Westra et al., 2013) . Therefore, we applied the Benjamini-Hochberg method to correct the maxT-adjusted p value significance by using only the most significant and independent SNPs per probe (tag SNPs). The number of tag eSNPs per cis-region was identified by LD pruning and ''clumping'' the SNPs using the ''clump'' command in PLINK (using distance < 1 Mb and r 2 % 0.2 as setting). Each tag SNP forms a SNP bin by aggregating SNPs at r 2 % 0.2 and distance < 1 Mb. SNPs within a given bin were correlated to the tag SNP, but not to any other tag SNP of an other SNP bin. We limited the false-positive SNP-probe pairs to less than 5% and therefore considered the FDR analog of the p value (Q value) < 5% as statistically significant.
Validation of GR-response cis-eQTL results was carried out with a sample size-weighted Z score meta-analysis in an additional independent dataset using peripheral blood samples of 58 individuals (see Supplemental Experimental Procedures). A GR-response cis-eQTL was validated if the meta-analysis p value was less than the actual maxTadjusted p value in the discovery sample alone.
The genomic control inflation factor (l gc ; Devlin and Roeder, 1999) was calculated for every GR-response eQTL gene expression probe (n = 297) based on the genome-wide genotype data (l gc ). The inflation factor was computed in PLINK as median c 2 statistic. The median l gc over all probes is 1, which implies no large inflation was present. We used NR3C1 ChIP-seq data obtained from the ENCODE Project (ENCODE Project Consortium, 2011) to determine actual GR binding at GRresponse eSNPs (see Supplemental Experimental Procedures).
To determine whether GR-response eSNPs were enriched for functional regions, we annotated them using HaploReg (Ward and Kellis, 2012 ) and compared the results to a realistic null distribution based on permuted baseline eSNP sets (see Supplemental Experimental Procedures).
ChIA-PET data were obtained from the UCSC Genome Browser (http:// hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeGisChiaPet; see Supplemental Experimental Procedures).
To identify whether GR-response eSNPs were enriched for association with MDD, SCZ, BPD, ADHD, ASD, Crohn's disease, rheumatoid arthritis, and the GWAS loci for height, we integrated our data with results from the previously published GWAS analysis (see Supplemental Experimental Procedures). To prove the significance of the MDD-related GR SNPs for MDD, we used a logistic regression model to test the association of the MDD-related GR tag eSNP GRPSs for disease status in the independent MARS cohort. Gender, BMI, and age were used as covariates. To establish the null distribution, we generated 1,000 random SNP profiles by swapping individual labels to provide new SNP profiles under the null hypothesis. To further account for the genomic LD structure, we limited the analyses to tag SNPs (tag SNP = SNP showing the highest association per cis-eQTL bin) and generated 1,000 randomized SNP sets; conditional on MAF and each of the same size as the GR-response tag SNPs overlap with MDD associations (n = 285).
The gene network analysis was performed using the online tool GeneMANIA (Montojo et al., 2014) . To establish the null-distribution, we calculated the gene network for ten sets of randomly chosen GR-response transcripts (n = 4,422). Finally, we determined the average gene network results in order to establish the relationship between MDD-relevant GR-response transcripts and non-MDD-relevant but GR-response transcripts. Network categories showing a fold enrichment > 1 are reported in Figure 6A .
For the co-expression analysis, we used the GR-response residuals from all array probes (n = 4,422) to determine if the 25 MDD-related GR array probes are more co-regulated than 1,000 sets of randomly chosen GR-stimulated transcripts (see Supplemental Experimental Procedures).
A disease-related network was built by manual curation and literature mining using the CIDeR database (Lechner et al., 2012) and the yED software (yWorks GmbH, Tü bingen).
To test the relationship of the GR-response eSNPs and threat-related amygdala reactivity, we used an imaging genetics strategy as described in the Supplemental Experimental Procedures.
Chromatin Conformation Capture Analysis 3C was carried out in five LCLs as described in Hagè ge et al., 2007 and detailed in the Supplemental Experimental Procedures.
qPCR Validation
Quantitative real-time PCR (qPCR) was used to validate the association between eSNPs and GR-stimulated gene expression of ADORA3 (the probe with the most significant GR-response eQTL) and HIST2H2AA3/HIST2H2AA4 (the probe with the most eSNPs overlapping with data from our meta-analysis for MDD) in whole blood cells and for a long-range GR-response eQTL-NRTN in five LCLs, which were also used with the 3C assay. More details are provided in Supplemental Experimental Procedures.
ACCESSION NUMBERS
Data from the human gene expression microarray experiment were deposited at the GEO repository under GEO: GSE46743. (A) Time course of gene expression changes after oral dexamethasone administration. The number of genes that are differently expressed at several time points after administration of 1.5 mg dexamethasone relative to baseline in 4 healthy male individuals are shown. The height of the bars indicates the total number of transcripts with nominally significant changes from baseline gene expression. Baseline blood samples were obtained at 6pm. This evening time point was chosen so that the stimulation experiments took place during the quiescent period of the stress hormone system. Baseline blood draws were immediately followed by oral administration of dexamethasone. Additional blood samples were drawn at 9pm and 11pm on the same day, at 8am and 6pm the next day and at 6pm on day 3. A comparison of baseline gene expression vs. gene expression after 3, 5, 14, 24 and 48 h shows an initial high number of gene expression changes, followed by a normalization within 24-48 hours. The highest number of differently expressed genes (highest bar in chart) was observed at 3 and 5 hours post dexamethasone ingestion. For practical reasons as well as to avoid secondary GR target effects, in the subsequent experiment we collected blood 3 hours after dexamethasone intake. (B), (C) Dexamethasone effect on cortisol and ACTH levels. Administration of dexamethasone resulted in a robust suppression of cortisol in all individuals. Cortisol levels were significantly suppressed in healthy controls (B; F 1,90 = 89.74, P = 3.57 x 10 -15 ) as well as in depressed patients (C; F 1,67 = 7.09, P = 0.0097) 3h after dexamethasone challenge. Similar results were observed for ACTH, with a significant reduction in ACTH levels in healthy controls B; F 1,91 = 43.96, P = 2.33 x 10 -9 ) and in depressed patients (C; F 1,65 = 9.75, P = 0.0027) after 3h. Disease-related network. For 22 of the 24 MDD-related GR genes a tightly interconnected diseaserelated network was generated from manually curated experimental data derived from the literature. Elements of the figure: Proteins from MDD-related GR genes (orange boxes), additional proteins and protein complexes (white boxes), biological processes (beige boxes), psychiatric disorders (blue boxes), drugs (green boxes), activating processes (green arrow-headed lines), inhibitory processes (red bar-headed lines) and interactions such as physical interactions, associations with diseases and differential regulation of signaling pathways (black line).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
Figure S4. Related to Figure 7.
(A) Elevated genetic risk profile scores (GRPSs) correlate with dysfunctional amygdala reactivity in the entire DNS sample (n = 647). As previously found in the European-American subsample, elevated GRPSs predicted blunted amygdala reactivity to threat-related expressions in comparison to neutral expressions in the entire sample when controlling for patterns of population stratification. Post-hoc analyses revealed that GRPS was not predictive of reactivity to threat-related expressions, but that higher GRPSs predicted elevated amygdala reactivity to neutral expressions, in comparison to nonface control stimuli. List of primers used for the qPCR for LONP1 and GAPDH in LCLs.
Target Gene
Primer Set (5'-3') LONP1 Forward: TTGGTGGCATCAAGGAGAAG Reverse: CGGTAGTGTTCCACGAAGTG GAPDH Forward: CCAAGGTCATCCATGACAAC Reverse: GAGGCAGGGATGATGTTCTG
Oligonucleotides for Chromatin Conformation Capture (3C).
Primer Sequence  C1  GCCTTACCCAGCACATTTTG  P1  CTGGAAGAGCTTGACCAAGTG  P2  CTCACTCCCCTTGCAATCTC  P3  ACTCGCTTTTTGCAGTAGGG  P4  TACCGCAGCCTACTGCATC  P5  CTTCCACACTGAATCTCACCTG  P6  ATCAATGACCCTCACTCCTCTC  P6 ATCAATGACCCTCACTCCTCTC Primer set for DNA quantification of 3C samples.
Primer Set (5'-3') Forward: TGGTGAAACCCCGTCTCTAC Reverse: AATCTCAGCTCACTGCAACC
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Samples and study design.
MPIP cohort.
The subject pool for the eQTL analysis consisted of 164 male Caucasian individuals (90% of German origin) recruited for the MARS project (Ising et al., 2009) reporting a history of current psychiatric, major neurological nor general medical disorders were included in the control sample. Recruitment strategies and further characterization of the MPIP cohort have been described previously . Of these participants, 4 were excluded due genotyping problems.
MARS cohort. This sample included 1,005 MDD patients (561 female, 444 males; age = 48.15 ± 14.13 years; HAM-D = 25.68 ± 6.5), as well as 478 controls (298 females, 180 males; age = 47.83 ± 13.7 years), recruited for the MARS project at the MPIP in Munich, Germany. All included patients were of European descent. Recruitment strategies and further characterization including population stratification of the MARS cohort have been described previously . All individuals used within the eQTL study (MPIP cohort) were not part of this sample.
DNS cohort.
All participants from the Duke Neurogenetics Study (DNS) provided informed written consent, prior to participation, in accord with the guidelines of the Duke University Medical Center Institutional Review Board. All participants were in good general health and free of the following DNS exclusion criteria: (1) medical diagnosis of cancer, stroke, diabetes requiring insulin treatment, chronic kidney or liver disease or lifetime psychotic symptoms; (2) use of psychotropic, glucocorticoid or hypolipidemic medication, and (3) conditions affecting cerebral blood flow and metabolism (e.g., hypertension). Current DSM-IV Axis I and select Axis II disorders (Antisocial Personality Disorder
and Borderline Personality Disorder) were assessed with the electronic Mini International Neuropsychiatric Interview (Sheehan et al., 1998) and Structured Clinical Interview for the DSM-IV Axis II (SCID-II) (First et al., 1997) respectively. These disorders are not exclusionary as the DNS seeks to establish broad variability in multiple behavioral phenotypes related to psychopathology.
On January 6 th , 2014, 726 participants had overlapping fMRI and genetic data that was fully processed and used for these analyses. Of these participants, 79 were excluded due to scanner-related artifacts in fMRI data (n = 6), incidental structural brain abnormalities (n = 2), a large number of movement outliers in fMRI data (n = 21; see ART description below), inadequate signal in our amygdala regions of interest (n = 14; see coverage description below), poor behavioral performance (n = 20; accuracy lower than 75%), outlier status according to ancestrally-informative principal components (n = 5), scanner malfunctions (n = 2), incomplete fMRI data collection (n = 1), and failed genotyping at one GRPS polymorphisms (without a proxy of r 2 > 0.9; n = 8). Thus, all imaging genetics analyses were conducted in a final European-American subsample of 306 participants (age = 19.72 ± 1.23 years; 148 males; 63 with DSM-IV Axis I disorder) and a full sample of 647 participants (age = 19.65 ± 1.24 years; 285 males; 117 with DSM-IV Axis I disorder; 306
European Americans, 72 African Americans, 170 Asians, 37 Latino/as, and 62 of Other/Multiple racial origins according to self-reported ethnicity; for a full description of diagnoses present in the sample see Table S5 ).
Mouse models.
The animal experiments were carried out in the animal facilities of the MPIP in Munich, Germany. Male C57BL/6N mice at an age of 12 weeks (mean bodyweight 26.8 ± 0.1 g) were used for the dexamethasone-stimulation test (DEX-mouse). The experiment was performed twice with two separate batches of mice (n = 22 per batch). Male 3-4 month old C57BL/6N mice (mean bodyweight 25.5 ± 2.12 g) were used for the acute social defeat mouse model (Stress-mouse). Two weeks before the experiment onset, mice were singly housed and acclimated to the experimental room. All mice (DEX and Stress-mice) were kept under a 12 h light/dark cycle and standard conditions. Food and tap water were available ad libitum. All efforts were made to minimize animal suffering during the experiment. The committee for the Care and Use of Laboratory animals of the Government of Upper Bavaria, Germany approved the protocols.
(i) DEX-mouse: Animals were injected i.p. with either vehicle (VEH, n = 11) or 10 mg/kg dexamethasone (DEX, n = 11) between 9am and 11am. Animals were sacrificed 4 hours post injection, blood was collected and the brains were carefully removed. The prefrontal cortex (PFC; batch 1), hippocampus (HC; batch 1) and amygdala (AM; batch 2)
were dissected immediately according to standard protocols (Spijker, 2011) . Amygdala preparation was as follows: brains were cut into ca. 1 mm thick slices using a custommounting device. The amygdala (all subnuclei) (Paxinos and Franklin, 2003) was manually dissected with a scalpel under visual control using a binocular microscope. HC and PFC preparation: brain regions were manually dissected from the whole brain by trained personnel. Dissected tissues were directly transferred into RNA lysis solution (Applied Biosystems, USA) and frozen at -80°C. In addition, 300 µl of trunk blood (batch 1) was collected into microcentrifuge tubes containing PaxGene RNA stabilizer solution and frozen at -20°C.
(ii) Stress-mouse: The acute social defeat stress paradigm lasted 5 min and was conducted as previously described . Briefly, experimental mice were placed in the home cage of a dominant aggressive CD1 resident mouse. Interaction between the mice was permitted for 5 min without any interference unless an animal was severely injured. When this was the case, the experimental animal was returned to his home cage and excluded from analysis. Prior to the experimental day, all CD1 resident mice received aggression tests to ensure dominance and were trained for aggressive behavior. The control mice were allowed to explore an empty cage (control condition) for 5 min. Exactly 4 h after the onset of the stress paradigm, the mice were sacrificed and the tissue harvested for subsequent analyses. Briefly, mice were anesthetized with Isofluorane and then immediately killed by decapitation. In the same manner as for the DEX-mouse, 250µl of trunk blood was collected and the brains were carefully removed. The same brain regions i.e. the HC, AM and PFC were dissected out, snap-frozen, and stored in RNA lysis solution at -80°C until needed.
Gene expression data.
Human whole blood of the MPIP cohort was collected using PAXgene Blood RNA Tubes (PreAnalytiX), processed as described previously and hybridized to Illumina HumanHT-12 v3.0 Expression Bead Chips. Samples had a mean RNA integrity number (RIN) of 7.97 ± 0.42 SD. The Illumina Bead Array Reader was used to scan the microarrays and summarized raw probe intensities were exported using Illumina's GenomeStudio v2011.1 Gene Expression module. Further processing was carried out using R version 2.14.0 (http://www.r-project.org/). All 48,750 probes present on the microarray were first filtered by an Illumina detection P value of 0.01 in at least 10% of the samples, leaving 14,168 expressed probes for further analysis. Each transcript was then transformed and normalized through variance stabilization and normalization (VSN) (Lin et al., 2008) .
Technical batches were adjusted using ComBat with fixed effects of amplification round (Johnson and Cheng, 2007) . To test for hidden confounding effects within the ComBat corrected data, we applied a surrogate variable analysis (Leek and Storey, 2007) . No significant surrogate variable could be identified suggesting that most of the confounding effects were captured by correcting for known batch effects. To further reduce batch effects baseline and dexamethasone stimulated RNA samples for each individual were processed within a single run. Finally for each probe, we constructed a linear model of the log fold change in gene expression between 6pm (baseline) and 9pm (GR-stimulation) standardized to 6pm (baseline) controlling for age, disease status and BMI. Models were implemented in "R" using the "lm" function. The residuals (GR-response residuals) from this regression were used as phenotype values in the following analyses. The results did not change when the RIN factor, the dexamethasone serum levels (3 hours following administration) and the differential blood cell count (levels of monocytes, granulocytes and lymphocytes) were included as additional independent covariates.
To control if significant eQTLs might be biased due to SNPs within the probes, the Illumina Table Browser (http://hgdownload.soe.ucsc.edu/goldenPath/hg18/database/refGene.txt.gz). The positions of the probes were annotated using ReMOAT and only autosomal probes were used for the GR-response eQTL analysis (n = 4,447 autosomal probes).
DEX-mouse und Stress-mouse RNA was extracted from whole blood using the PAXgene blood miRNA kit (PreAnalytiX) according to (Krawiec et al., 2009) . RNA was extracted from the mouse brain regions using RNeasy Plus Universal Mini Kit (Qiagen) in the DEX-mouse experiment and using TRIzol (Life Technologies) in the Stress-mouse experiment, both according to manufacturer's protocol. RNA was quality checked using the Figure 6B .
Genotype data.
Human DNA of the MPIP cohort samples was isolated from EDTA blood samples using the Gentra Puregene Blood Kit (Qiagen) with standardized protocols. Genome-wide SNP genotyping was performed using Illumina Human610-Quad and Illumina Human660W-Quad
Genotyping BeadChips according to the manufacturer's standard protocols. In total, 582,539 genetic markers in 163 individuals of the MPIP cohort could be successfully genotyped.
Individuals with low genotyping rate (<98%) and SNPs showing significant deviation from the Hardy-Weinberg equilibrium (HWE, P value < 1 × 10 -5 ) were excluded. Similarly, a low minor allele frequency (MAF;<10%) and SNPs with high rates of missing data (>2%) were excluded. This resulted in 436,643 SNPs and 160 individuals for further analysis. In the 160 samples that passed the quality control, imputation of additional variants was performed using IMPUTE v2 ) on the basis of HapMap CEU Phase 3 (International HapMap Consortium, 2003) and 1,000 Genomes Project version June 2010 (hg18) CEU data for ~8 million SNPs (Durbin et al., 2010) . Imputed SNPs were excluded if their posterior probability averages were less than 90% for the most likely imputed genotype (INFO ≥ 0.9).
SNPs were also excluded if their call rate was less than 98%, HWE P value was less than 1×10 -5 and MAF < 10%. This yielded a total of 2,011,895 SNPs. To annotate SNPs for the closest gene, we used Annovar version November 2011 (Wang et al., 2010) with the RefSeq gene annotation SNP coordinates are given according to hg18.
Human DNA of the MARS cohort samples was extracted from EDTA blood samples using the Gentra Puregene Blood Kit (Qiagen) with standardized protocols. Whole-genome SNP genotyping was performed on Illumina Sentix Human-1, HumanHap300, Human610-Quad and HumanOmniExpress Genotyping BeadChips according to the manufacturer's standard protocols. Individuals as well as the genotype data have been subjected to the same quality control steps as the MPIP cohort (genotyping rate < 98%, MAF < 10%, HWE P value < 1 × 10 -5 , SNP missingness < 98%). Missing genotype data were imputed via IMPUTE v2 based on the 1,000 Genomes Project version Nov. 2010 ALL reference panel.
The MDD-related GR eSNP profile was derived from loci associated with both dexamethasone-induced differences in gene expression and MDD. It included alleles from 20 of the 23 tag eSNPs (3 SNPs diverged from HWE in the MARS sample, Table S3 . Non-risk and risk alleles (according to association with depression in the PGC dataset) were coded 0 and 1, respectively, and summed in an additive fashion to create cumulative genetic risk profile scores (GRPS; 0 ,1 ,2). The MARS GRPSs ranged from 12-30.
Human DNA from participants of the DNS cohort was isolated from saliva derived from Oragene DNA self-collection kits (DNA Genotek) customized for 23andMe. DNA extraction and genotyping were performed by the National Genetics Institute (NGI), a CLIAcertified clinical laboratory and subsidiary of Laboratory Corporation of America. The Illumina
HumanOmniExpress BeadChips and a custom array containing an additional ~300,000
SNPs were used to provide genome-wide data. Due to differences in genotyping array content the DNS GRPSs included alleles from 19 of the 23 eSNPs (Table S4 ) and were coded in the same way as the MARS GRPSs. All SNPs used for the GRPSs had genotyping rates < 97%, MAF < 10%, HWE P value < 1 × 10 -5 (Table S4) . DNS GRPSs ranged from 10-28 and were normally distributed (Figure 7) . To account for differences in ancestral background in the full sample, we used EIGENSTRAT (v, 5.0.1) (Price et al., 2006) to generate principal components and included the first 5 components as covariates in the analysis. Five participants were outliers for these components (± 6 SD from the mean on one of the top ten components) and hence were excluded from analyses.
DNS neuroimaging protocol.
BOLD fMRI paradigm.
A widely used and reliable challenge paradigm was employed to elicit amygdala reactivity.
The paradigm consists of 4 task blocks requiring face-matching interleaved with 5 control blocks requiring shape-matching (see Figure S4D ). In each face-matching trial within a block, participants view a trio of faces derived from a standard set of facial affect pictures (expressing angry, fearful, surprised, or neutral emotions), and select which of the 2 faces presented on the bottom row of the display matches the target stimulus presented on the top row. Each emotion-specific block (e.g., fearful facial expressions only) consists of 6 individual trials, balanced for gender of the face. Block order is pseudo-randomized across participants.
Each of the 6 face trios is presented for 4 seconds with a variable inter-stimulus interval of 2-6 seconds; total block length is 48 seconds. In the shape-matching control blocks, participants view a trio of geometric shapes (i.e., circles, horizontal and vertical ellipses) and select which of 2 shapes displayed on the bottom matches the target shape presented on top. Each control block consists of 6 different shape trios presented for 4 seconds with a fixed inter-stimulus interval of 2 seconds, comprising a total block length of 36 seconds. The total paradigm was 390 seconds in duration. Reaction times and accuracy are recorded through an MR-compatible button box.
BOLD fMRI acquisition.
Participants were scanned using a research-dedicated GE MR750 
BOLD fMRI data analysis.
The general linear model of Statistical Parametric Mapping 8 (SPM8) (http://www.fil.ion.ucl.ac.uk/spm) was used for whole-brain image analysis. Individual subject data were first realigned to the first volume in the time series to correct for head motion before being spatially normalized into the standard stereotactic space of the Montreal Neurological Institute (MNI) template using a 12-parameter affine model. Next, data were smoothed to minimize noise and residual differences in individual anatomy with a 6mm FWHM Gaussian filter. Voxel-wise signal intensities were ratio normalized to the whole-brain global mean. Then the ARTifact Detection Tool (ART;
https://www.nitrc.org/docman/view.php/104/390/Artifact%20Detection%20Toolbox%20Manu al) was used to generate regressors accounting for images due to large motion (i.e., > 0.6 mm relative to the previous time frame) or spikes (i.e., global mean intensity 2.5 standard deviations from the entire time series). Participants for whom more than 5% of acquisition volumes were flagged by ART (n = 21) were removed from analyses. An region of interest (ROI) mask (Automated Anatomical Labeling (AAL) atlas) from WFU pickatlas (Maldjian et al., 2003) was used to ensure adequate amygdala coverage for the face-matching and number-guessing tasks, respectively. Participants who had less than 90% coverage of the amygdala (n = 14) were excluded from analyses.
Following preprocessing steps outlined above, linear contrasts employing canonical hemodynamic response functions were used to estimate task-specific (i.e., "Angry & Fearful
Faces > Neutral Faces", "Angry & Fearful > Shapes", "Neutral > Shapes") BOLD responses for each individual. The primary contrast of "Angry & Fearful > Neutral" was used to assay centromedial reactivity to cues that are conditioned social signals to threat in the environment (i.e., angry and fearful expressions) relative to signals that do not convey threat information about the environment (i.e., neutral expressions). Post-hoc analyses using the "Angry & Fearful > Shapes" and "Neutral > Shapes" contrasts were used to discern if the association with GRPS reflected relatively decreased reactivity to angry and fearful expressions or increased reactivity to neutral expressions. Individual contrast images (i.e., weighted sum of the beta images) were used in second-level random effects models accounting for scan-toscan and participant-to-participant variability to determine mean contrast-specific responses using one-sample t-tests. A voxel-level statistical threshold of P value < 0.05, family wise error corrected for multiple comparisons across the bilateral centromedial amygdala ROIs, and a cluster-level extent threshold of 10 contiguous voxels was applied to these analyses.
The bilateral centromedial amygdala ROIs were defined using anatomical probability maps (Amunts et al., 2005) . The centromedial ROI was chosen because it includes the central nucleus of the amygdala (CeA). This specifically functions to drive physiologic, attentive, and neuromodulatory responses to threat, as opposed to the basolateral complex of the amygdala (BLA), which primarily functions to relay information to the CeA. Thus, the expression of stress responsive behavior is more closely linked with the activity of the CeA and not the BLA (Davis and Whalen, 2001; LeDoux, 2007) . Human research using such distinctions has shown that ROIs encompassing the CeA or BLA differentially respond to stimuli and share different patterns of functional as well as structural connectivity (Brown et al., 2014; Etkin et al., 2004; Lerner et al., 2012) .
BOLD parameter estimates from a cluster within the left centromedial amygdala ROI exhibiting a main effect for the "Angry & Fearful > Neutral" contrast were extracted using the VOI tool in SPM8 and exported for regression analyses in SPSS (v.18) . No significant cluster emerged in the right centromedial amygdala. Extracting parameter estimates from clusters activated by our fMRI paradigm, rather than those specifically correlated with our independent variables of interest, precludes the possibility of any correlation coefficient inflation that may result when an explanatory covariate is used to select a region of interest.
We have successfully used this strategy in prior studies (Bogdan et al., 2012) .
Statistical Analysis.
Cis-associations of baseline gene expression.
Using baseline gene expression of the 4,447 differently regulated autosomal array probes 
Validation GR-response cis-eQTL results
Validation of GR-response cis-eQTL results was carried out with a sample size-weighted Z-score meta-analysis in an additional independent data set using peripheral blood samples (baseline and after GR-stimulation with 1.5 mg dexamethasone) of 58 individuals (21 male controls, 14 male cases and 23 female cases). We applied the same strategy as used in the discovery sample (MPIP cohort) to filter, normalize and batch correct the gene expression data. We adjusted the analysis for the same covariates plus gender; applied the same SNP quality control checks and performed the cis-eQTL mapping in PLINK.
Enrichment of GR binding regions
To identify whether GR-response eSNPs were enriched for GR binding sites, we used the ENCODE (ENCODE Project Consortium, 2011) NR3C1 ChIP-seq data from GM12878 LCLs (accession: ENCSR904YPP) from which no aligned tracks are currently available. Raw data were download at https://www.encodeproject.org/experiments and initial filtering was performed using FASTX Toolkit (v. 0.0.14, http://hannonlab.cshl.edu/fastx_toolkit/index.html)
and Prinseq (v. 0.20. 3) (Schmieder and Edwards, 2011) to eliminate artifacts and low quality reads. Alignment on hg19 was performed using BWA (v. 0.7.10) (Li and Durbin, 2009) allowing only uniquely mappable alignments with alignment quality of above 20. Reads from both ChIP and both control libraries were pooled leading to 46,453,650 and 68,227,580 used reads, respectively. Peak-calling was carried out by MACS14 (v. 1.4.2) (Zhang et al., 2008) using default settings, resulting in around 23,000 annotated signals. The average length of a ChIP signal as defined by the peak calling was 746.3 bps ± 370.6 bsp.
We mapped the GR-response eSNPs to these GR ChIP-seq peaks and compared the overlap observed with 1,000 equal sized sets of randomly drawn SNPs (n=3,662 SNPs) from of all analyzed SNPs (without replacement) matched in MAF (=null distribution). To match the MAF distributions of the random SNP sets with our GR-response eQTL data we ! 22 divided the SNPs into non-overlapping MAF bins, each of the width 0.05 as described previously . For every set we counted the percentage of SNPs within a GR ChIP-seq peak. Enrichment calculations with a permutation-based FDR < 10% were considered as statistically significant within the entire manuscript.
Enhancer enrichment analysis
We investigated whether GR-response eSNP binds are enriched for functional enhancer annotations using the online tool HaploReg version 2 (Ward and Kellis, 2012) based on the Roadmap Epigenome data (Roadmap Epigenomics Consortium et al., 2015) and using the 1,000 Genomes Project CEU data as a background data set. Additionally we performed the enrichment analysis on ten permuted baseline eSNP bin sets (size matched) to generate a realistic null distribution. The average enhancer enrichment over the ten permutations is present in Figure 3 and S2.
Chromatin interaction analysis with paired-end tag (ChIA-PET) mapping.
The combined set of the first two replicates of the RNA Polymerase II ChIA-PET data ) generated from K562 chronic myeloid leukemia cell lines (n > 400,000 interaction regions) was obtained from the UCSC Genome Browser (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeGisChiaPet/).
Genomic coordinates of our GR-response eSNP bins were converted from hg18 to GRCh build 37 (hg19) using the UCSC Genome Browser liftOver tool (http://genome.ucsc.edu/cgibin/hgLiftOver) and the probe gene coordinates were updated with the hg19 RefSeq (Pruitt et al., 2012) gene table obtained from the UCSC Table Browser (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/refGene.txt.gz; excluding 15
probe genes on hg19). To estimate the overlap of the direct chromatin interactions and GRresponse eQTL bins (eSNP bin-probe gene combination) we tested if one ChIA-PET tag overlapped with the region of the eSNP bin ± 10kb as well as the relevant array probe gene (10kb ± transcription start or end). To establish the null distribution, we permuted the distances between the GR-response eSNP bins and the transcription sites of the corresponding probe gene (n = 270 updated to hg19) and estimated the overlap with ChIA-PET interaction signals. We repeated the analysis 1,000 times and for each set we counted the number of genes with overlapping ChIA-PET data.
Enrichment of GWAS susceptibility markers.
To identify whether GR-response eSNPs were specifically enriched for association with psychiatric disorders and not with other diseases or traits, we generated 1,000 sets of permuted baseline eSNPs (conditional on MAF and number of GR-response eSNPs overlapping with the respective GWAS). For every set we counted the percentage of unique SNPs with a GWAS results at P value ≤ 0.05. On this basis we constructed the null distribution. A second null distribution was created based on all imputed SNPs of high quality.
1.) PGC MDD data: The MDD GWAS data was generated by conducting a metaanalysis based on the Psychiatric Genomics Consortium (PGC) GWAS mega-analysis for MDD (Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, 2012) data . We used the "meta-analysis" function in PLINK assuming a fixed effect model in 17,846 individuals of European ancestry (8,864 cases with MDD and 8,982 controls) from 8 of the 9 studies included in the PGC MDD data. All samples from the initial PGC MDD data (n = 18,759) that overlapped with our MARS cohort (n = 376 cases and 537 controls) were excluded, which was then used as validation sample. The PGC MDD analysis used SNP data imputed to the 1,000 Genomes Project (hg19). 4.) Non psychiatric trait data: The GWAS data for height (Heid et al., 2010) and rheumatoid arthritis (RA) (Stahl et al., 2010) were obtained from the PGC website For comparability we converted all our SNP coordinates to the relevant genome assembly of analyzed GWAS data using the UCSC Genome Browser liftOver tool.
Co-expression analysis
For the co-expression analysis we used the GR-response residuals from all array probes (n = 4,447) to determine if the 25 MDD-related GR array probes are more co-regulated than 1,000 sets of randomly chosen GR-stimulated transcripts. To realize this, we carried out a co-expression analysis in R using the function "dist" specifying the Euclidian distance as distance measure and calculated the mean distance of all pair-wise distances. We established the significance of co-expression network of the 25 MDD-related GR array probes by testing the observed mean distance versus the null distributions created by calculating the mean distance of all pair-wise distances for 1,000 sets of 25 randomly chosen GR-stimulated transcripts. Next, we determined the number of sets, having lower mean distances than the actual MDD-related GR transcripts to measure the enrichment statistic.
DNS neuroimaging analysis.
Statistical analyses of the imaging data were completed using linear regression in SPSS to test the association of the MDD-related GR tag eSNP GRPSs to amygdala reactivity in the independent DNS cohort. To maintain variability but constrain the influence of extreme outliers, prior to any analyses, all imaging variables were winsorized (i.e., following data quality control procedures, outliers more than ± 3 SD were set at ± 3 SD from the mean; for the "Angry and Fearful > Neutral faces" contrast, 13 outliers (2.01%) of the entire sample were moved to ± 3 SD from the mean). Gender, psychiatric diagnosis (0,1) and age were entered as covariates for both EUR-AM and entire sample analyses. Five ancestrallyinformative principal components that distinguish the sample were added as additional covariates in the analyses of the entire sample. We computed permutations (n = 1,000) in which we constructed randomly generated SNP profiles that were matched for MAF, amount of SNPs (n = 19) and constrained by the max LD observed within the sample.
Graphs were generated with Haploview (Barrett et al., 2005) , ggplot2 ( (Wickham, 2009 ) and Circos (Krzywinski et al., 2009) .
Chromatin conformation capture
Five human lymphoblastoid cell lines were cultured in RMPI media with stable l-glutamine (Biochrom) supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic (Life Technologies). Crosslinking and cell lysis were performed as described (Hagège et al., 2007) . Nuclei were digested using 1,000 U of NcoI. Subsequent re-ligation, de-crosslinking and purification were conducted according to the manufacturer's protocol. Following assessment of digestion efficiency and sample purity, DNA concentration of the 3C samples were determined by SybrGreen quantitative PCR using an "internal" primer set (see Table   S6 ; primers that do not amplify across sites recognized by the restriction enzyme used) as described in (Hagège et al., 2007) . Primers were designed with an anchor primer in the fragment containing the TSS of LONP1 and in potential interacting fragments in and around eSNP bin of NRTN using Primer3Plus (http://www.bioinformatics.nl/cgibin/primer3plus/primer3plus.cgi). Quantitative PCR was carried out using ABsolute Blue (Hagège et al., 2007) and is presented as relative crosslinking frequency. Primers used for the chromatin conformation capture interaction studies are listed in Table S6 . Linear mixed models were used for statistical analysis.
Quantitative real-time PCR (qPCR) validation.
Total RNA was reverse-transcribed to cDNA using random primers and the Superscript II reverse transcriptase (Invitrogen) for qPCR to validate microarray results. qPCR was carried out according to manufactures instructions using Roche-LightCycler 480 System (Roche Applied Science) and assays were designed using the Roche Universal Probe Library (http://qpcr.probefinder.com) for ADORA3 (the probe with a significant GR-response eQTLs), HIST2H2AA3/4 (the probe with the most eSNPs overlapping with the meta-analysis results for MDD) and TBP as the endogenous control gene. Assays for LONP1 and GADPH were designed using Primer3Plus (http://www.bioinformatics.nl/cgibin/primer3plus/primer3plus.cgi). The association between eSNPs and GR-stimulated gene expression of the target genes could be validated using qPCR (see Figure 2C ,D and 4A,B).
Sequences of primers used are summarized in Table S6 . All samples were run in duplicates and duplicates discordant in CT values by more than 0.2 cycles, were excluded from the analysis. Relative gene transcript levels were determined by Pfaffl's equation (Pfaffl, 2001) with: ratio = ! . qPCR ratios shown in Figure 2D and were calculated using the following equations:
!"# = .
qPCR validation results.
Two transcript variants encoding isoforms with a different 3'UTR length have been identified for HIST2H2AA3/4. The shorter gene product (isoform 1) is annotated by RefSeq while the alternatively spliced longer gene product (isoform 2) is annotated by Ensembl release 54 (HIST2H2AA3-001; ENST00000369161) and further predicted by AceView (HIST2H2AA3.aApr07-unspliced, HIST2H2AA4.aApr07-unspliced). This longer isoform is tagged by the significant Illumina probe (ILMN_1695435). Hence we designed two different assays-one covering the common part of both isoforms (assay 1) and the other tagging isoform 2 (assay 2). The expression levels measured with both assays were highly correlated (Spearman's test P value < 1.5 × 10 -20 , R = 74%). We could replicate a significant SNP effect in 137 samples with a P value of 0.012 using assay 1 with a genotypic model and P = 0.017 using a carrier model, with the same direction of change as in the expression array.
